Among the recent approaches under development for the cardiovascular prevention, vaccines against PCSK9 could be a better alternative than monoclonal antibodies [13, 48]; they would be less expensive, do not require frequent administrations, and could be part of a primary prevention strategy aimed at achieving optimal LDL-C levels among subjects who do not have clinical evidence of cardiovascular disease. The gene discussed is PCSK9; the disease is cardiovascular disorder.